Sulopenem - Iterum Therapeutics
Alternative Names: CP-70,429Latest Information Update: 27 Aug 2024
At a glance
- Originator Pfizer
- Developer Iterum Therapeutics; Pfizer
- Class Anti-infectives; Antibacterials; Aza compounds; Beta-lactams; Esters; Penems; Small molecules
- Mechanism of Action Cell wall inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Urinary tract infections
- No development reported Intra-abdominal infections
- Discontinued Bacterial infections; Community-acquired pneumonia
Most Recent Events
- 13 Jun 2024 Pharmacodynamics data from a preclinical trial in Bacterial infection presented at the ASM Microbe 2024 (ASM-2024)
- 11 Oct 2023 Pharmacodynamics data from a preclinical trial in Bacterial infections presented at the IDWeek 2023 (IDW-2023)
- 15 Jun 2023 Antimicrobial data from a phase III SURE-2 trial in Urinary Tract Infection presented at the American Society for Microbiology Conference (ASM Microbe-2023)